infohep news

• Treatment for people who use drugs

  Barriers to HCV treatment access from the drug user's point of view: stigma, complex lives and damaged veins

  Keith Alcorn / 16 January 2019

  Despite access to hepatitis C treatment, many people who inject drugs still perceive numerous barriers to starting treatment, including the attitudes of healthcare workers, the difficulty of juggling treatment with competing demands, a ...

• International policy

  Lancet commission sets agenda for the elimination of viral hepatitis

  Keith Alcorn / 10 January 2019

  Viral hepatitis leads to around 1.3 million deaths a year, approximately 257 million people are living with hepatitis B virus (HBV) and 71 million with hepatitis C virus (HCV). Viral hepatitis ...

• Antiviral therapy

  Tenofovir alafenamide for hepatitis B shows improved kidney and bone safety after a year

  Liz Highleyman / 08 January 2019

  Tenofovir alafenamide (TAF; Vemlidy), the new formulation of tenofovir, continues to appear at least equally effective for treatment of hepatitis B but with a better safety profile than the older tenofovir disoproxil fumarate ...

• Treatment for people living with HIV and HCV

  Co-infection with HIV and HCV does not increase the risk of end-stage liver disease or liver cancer

  Keith Alcorn / 04 January 2019

  People with HIV and hepatitis C are no longer at higher risk of end-stage liver disease than people with hepatitis C alone, and the trend is probably associated with the improved effectiveness ...

• NAFLD

  Aramchol reduces liver fat in people with NASH

  Liz Highleyman / 02 January 2019

  A novel type of experimental therapy led to a significant reduction in liver fat and improvement in liver health among people with non-alcoholic steatohepatitis (NASH), according to study presented at the recent AASLD Liver ...